Spago Nanomedical Q2 operating loss widens to SEK 7.41 million

• Spago Nanomedical posted a Q2 net loss of SEK 7.33 million, widening from SEK 6.96 million a year earlier.
• Net sales were nil in Q2, swinging from SEK 81,000 in the year-ago quarter; cash rose to SEK 32.51 million at quarter-end.
• Operating expenses edged up to SEK 8.42 million from SEK 8.29 million; earnings per share improved to SEK -0.01 from SEK -0.02.
• Tumorad-01 DMC said the maximum tolerated dose endpoint was met at 20 MBq/kg; two more patients planned at 15 MBq/kg.
• CEO Mats Hansen said Tumorad development will focus on head and neck cancer, starting with adenoid cystic carcinoma as an orphan indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spago Nanomedical AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.